nVerses Capital LLC Increases Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

nVerses Capital LLC lifted its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 1,600.0% during the second quarter, HoldingsChannel reports. The firm owned 1,700 shares of the specialty pharmaceutical company’s stock after purchasing an additional 1,600 shares during the quarter. nVerses Capital LLC’s holdings in Collegium Pharmaceutical were worth $55,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently added to or reduced their stakes in the company. Gladius Capital Management LP purchased a new position in Collegium Pharmaceutical in the second quarter valued at about $32,000. Principal Securities Inc. purchased a new position in Collegium Pharmaceutical in the fourth quarter valued at approximately $40,000. Sheaff Brock Investment Advisors LLC bought a new position in Collegium Pharmaceutical during the first quarter valued at $204,000. Assetmark Inc. increased its position in Collegium Pharmaceutical by 25.5% in the fourth quarter. Assetmark Inc. now owns 5,445 shares of the specialty pharmaceutical company’s stock worth $168,000 after buying an additional 1,108 shares during the last quarter. Finally, Gallacher Capital Management LLC bought a new stake in shares of Collegium Pharmaceutical in the first quarter valued at $223,000.

Collegium Pharmaceutical Stock Performance

NASDAQ COLL opened at $38.24 on Thursday. The company’s 50 day simple moving average is $34.80 and its two-hundred day simple moving average is $35.28. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.11 and a quick ratio of 1.04. Collegium Pharmaceutical, Inc. has a 1 year low of $20.95 and a 1 year high of $40.95. The stock has a market capitalization of $1.25 billion, a PE ratio of 15.93 and a beta of 0.94.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.22. Collegium Pharmaceutical had a return on equity of 107.62% and a net margin of 17.32%. The company had revenue of $145.28 million for the quarter, compared to the consensus estimate of $143.94 million. During the same quarter last year, the business posted $1.13 earnings per share. The firm’s revenue was up 7.2% compared to the same quarter last year. Analysts predict that Collegium Pharmaceutical, Inc. will post 5.89 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Needham & Company LLC reissued a “hold” rating on shares of Collegium Pharmaceutical in a report on Friday, August 9th. Truist Financial boosted their price target on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a “buy” rating in a research report on Friday, August 9th. HC Wainwright raised shares of Collegium Pharmaceutical from a “neutral” rating to a “buy” rating and set a $47.00 price objective for the company in a report on Tuesday, July 30th. Piper Sandler reissued a “neutral” rating and set a $37.00 target price (down previously from $39.00) on shares of Collegium Pharmaceutical in a report on Friday, August 9th. Finally, Jefferies Financial Group raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and raised their price target for the stock from $41.00 to $44.00 in a report on Friday, June 7th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $42.00.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.